Calcineurin inhibitors in pediatric atopic dermatitis: A review of current evidence

American Journal of Clinical Dermatology

Volumn 12, Issue 1, 2011, Pages 15-24

  Kalavala, Manjunatha ^a   Dohil, Magdalene A ^b  

^a PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atopic dermatitis, treatment; Calcineurin inhibitors, adverse reactions; Calcineurin inhibitors, therapeutic use; Children; Pimecrolimus, adverse reactions; Pimecrolimus, therapeutic use; Tacrolimus, adverse reactions; Tacrolimus, therapeutic use; Topical

Indexed keywords

ALCLOMETASONE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE ACETATE; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE REACTION; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; CARCINOGENICITY; CHILD; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DNA DAMAGE; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MEGADOSE; DRUG STRUCTURE; ERYTHEMA; HUMAN; IMMUNOREACTIVITY; INFECTION RISK; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ATROPHY; SKIN INFECTION; SKIN LYMPHOMA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 78649642433     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11319300-000000000-00000     Document Type: Review

References (71)

1. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis: a genetic-epidemio-logic studyin a population-based twin sample. J Am Acad Dermatol 1986; 15: 487-94
2. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the pre-valence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125-38
3. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon school children. J Am Acad Dermatol 2000; 43: 649-55
4. Fleming S, Bodner C, Devereux G, et al. An application of the United Kingdom working party diagnostic criteria for atopic dermatitis in Scottish infants. J Invest Dermatol 2001; 117: 526-30
5. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998; 351: 1715-21
6. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159-62
7. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60: 984-92
8. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-94
9. Grewe M, Walther S, Gyufko K, et al. Analysis of the cytokine pattern ex-pressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995; 105: 407-10
10. Taha RA, Leung DY, Ghaffar O, et al. In vivo expression of cytokine receptor mRNA in atopic dermatitis. J Allergy Clin Immunol 1998; 102: 245-50
11. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6
12. Falangan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991; 352: 803-7
13. Loh C, Shaw KT, Carew J, et al. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem 1996; 271: 10884-91
14. Rao A. NF-ATp: a transcription factor required for the co-ordinated induction of several cytokine genes. Immunol Today 1994; 15: 274-81
15. Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52
16. Liu J, Farmer Jr JD, Lane WS, et al. Calcineurin is a common target of cy-clophillin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15
17. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41
18. Meingassner JG, Kowalsky E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149: 853-7
19. Yan J, Chen S, Wang X, et al. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 2008; 25: 117-20
20. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44
21. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (1 Suppl.): S47-57
22. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pime-crolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504
23. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62
24. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacro-limus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (1 Suppl.): S58-64
25. Zuberbier T, Brautigam MJ. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. Eur Acad Dermatol Venereol 2008; 22: 718-21
26. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic der-matitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
27. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2
28. Paller AS, Eichenfield LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008; 122: e1210-8
29. Thaci D, Reitamo S, Gonzalez Ensent MA, et al. Proactive disease manage-ment with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-56
30. Breneman D, Fleischer Jr AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly application of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008; 58: 990-9
31. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46
32. Reitamo S, Harper J, Bos JD, et al. 0.03% tacrolimus ointment applied once or twice daily ismore efficaciousthan 1%hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-62
33. Ashcroft DM, Chen LC, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007; (4): CD005500
34. Kubota Y, Yoneda K, Nakai K, et al. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study. J Am Acad Dermatol 2009; 60: 212-7
35. Kempers S, Boguniewicz M, Carter E, et al. Comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03% in paediatric patients with atopic eczema. J Am Acad Dermatol 2004; 51: 515-25
36. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more ef-fective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-22
37. Spergel J, Prenner B, Rico MJ. Tacrolimus ointment is a safe and effective treatment for mild atopic dermatitis [poster]. American Academy of Allergy, Asthma and Immunology 60th Annual Meeting; 2003 Mar 7-12; Denver (CO): P349
38. US Food and Drug Administration Center for Drug Evaluation and Research. Medical officer's review of new drug application 21-302: Elidel (pimecrolimus cream) approval package [online]. Available from URL: http://www.access data.fda.gov/drugsatfda-docs/label/2001/21302/lbl.pdf [Accessed 2010 Oct 24]
39. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin in-hibitors in atopic dermatitis. Br J Dermatol 2004; 151: 3-27 (Pubitemid 40023628)
40. Pournaras CC, Lubbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol 2001; 116: 480-1
41. Remitz A, Kyllonen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001; 107: 196-7
42. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-55
43. Stalder JF, FleuryM,SourisseM,et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131: 536-40
44. Fleischer Jr AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70
45. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis: the European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006
46. Stiehm ER, Roberts RL, Kaplan MS, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005; 53 (2 Suppl. 2): S206-13
47. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8
48. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin de-rivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13
49. Kyllonen H, Remitz A, Mandelin JM, et al. Effects of one-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-81
50. Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SDZ ASM 981, in patients with atopic dermatitis. Dermatology 2002; 204: 63-8
51. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144: 781-7
52. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76
53. Ruzicka T, Bieber T, Schoepf E, et al., the European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21
54. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic derma-titis. Curr Opin Pediatr 2002; 14: 414-8
55. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9: 165-9
56. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-50
57. Bens G, Boralevi F, Buzenet C, et al. Topical treatment of Netherton's syn-drome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003; 149: 224-6
58. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156: 203-11
59. Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclo-butane dipyridimine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006; 15: 342-6
60. Naylor N, Elmets C, Jaracz E, et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatol Treat 2005; 16: 149-53
61. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-95
62. Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31: 185-98
63. Protopic® (tacrolimus ointment): US prescribing information. Deerfield (IL): Astellas Pharma US Inc. 2006 Jan
64. Elidel® (pimecrolimus 1% cream): US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corp. 2006 Jan
65. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16
66. Fonacier L, Spergel J, Charleworth EN, et al. Report of the calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115: 1249-53
67. Pediatric Advisory Committee Meeting of the US Food and Drug Administration. Novartis and Fujisawa FDA briefing statements [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2. htm [Accessed 2010 Oct 24]
68. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 2006; 142: 633-7
69. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818-23
70. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77-8
71. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Med Gen Med 2006; 8: 8